Adenophorae Radix Reduces Fibrosis in a Bleomycin-Induced Pulmonary Fibrosis Mouse Model

Eui-Joong Kim, Jiwon Park, Chang-hwan Yu, Jae-Woo Park, Kwan-il Kim, Hee-Jae Jung, Jang-Hoon Kim, Y. Bu, Beom-joon Lee
{"title":"Adenophorae Radix Reduces Fibrosis in a Bleomycin-Induced Pulmonary Fibrosis Mouse Model","authors":"Eui-Joong Kim, Jiwon Park, Chang-hwan Yu, Jae-Woo Park, Kwan-il Kim, Hee-Jae Jung, Jang-Hoon Kim, Y. Bu, Beom-joon Lee","doi":"10.1177/1934578x241227490","DOIUrl":null,"url":null,"abstract":"Background: A screening study investigated the effects of lung-moistening herbal medicines on a bleomycin-induced pulmonary fibrosis mouse model and reported that the efficacy of Adenophorae Radix (ADR) was higher than that of other remedies. Objectives: This study aimed to investigate the antifibrotic efficacy and mechanism of action of ADR in a mouse model of bleomycin-induced pulmonary fibrosis. Materials and Methods: ADR water extract was prepared and orally administered at doses of 30, 100, and 300 mg/kg for 10 days after intratracheal bleomycin instillation. Changes in the body weight and lung histology were assessed. In addition, the quantity of inflammatory cells in the bronchoalveolar lavage fluid (BALF) and the level of transforming growth factor-β and α-smooth muscle actin (α-SMA) were measured. Results: ADR treatment decreased the degree of histological fibrosis based on the Ashcroft score and the number of inflammatory cells in BALF. Moreover, α-SMA level in the lung tissue decreased. ADR at 300 mg/kg resulted in the most significant reduction in the measured indicators. Conclusion: The results indicate that the administration of 300 mg/kg ADR attenuates pulmonary fibrosis in an animal model of idiopathic pulmonary fibrosis; thus, ADR can be considered as a candidate treatment for lung fibrosis.","PeriodicalId":509851,"journal":{"name":"Natural Product Communications","volume":"158 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Natural Product Communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1934578x241227490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A screening study investigated the effects of lung-moistening herbal medicines on a bleomycin-induced pulmonary fibrosis mouse model and reported that the efficacy of Adenophorae Radix (ADR) was higher than that of other remedies. Objectives: This study aimed to investigate the antifibrotic efficacy and mechanism of action of ADR in a mouse model of bleomycin-induced pulmonary fibrosis. Materials and Methods: ADR water extract was prepared and orally administered at doses of 30, 100, and 300 mg/kg for 10 days after intratracheal bleomycin instillation. Changes in the body weight and lung histology were assessed. In addition, the quantity of inflammatory cells in the bronchoalveolar lavage fluid (BALF) and the level of transforming growth factor-β and α-smooth muscle actin (α-SMA) were measured. Results: ADR treatment decreased the degree of histological fibrosis based on the Ashcroft score and the number of inflammatory cells in BALF. Moreover, α-SMA level in the lung tissue decreased. ADR at 300 mg/kg resulted in the most significant reduction in the measured indicators. Conclusion: The results indicate that the administration of 300 mg/kg ADR attenuates pulmonary fibrosis in an animal model of idiopathic pulmonary fibrosis; thus, ADR can be considered as a candidate treatment for lung fibrosis.
腺嘌呤核苷能减轻博莱霉素诱导的肺纤维化小鼠模型的纤维化程度
背景:一项筛选研究调查了润肺中药对博莱霉素诱导的肺纤维化小鼠模型的影响,结果表明腺嘌呤核苷(ADR)的疗效高于其他药材。研究目的本研究旨在探讨ADR在博莱霉素诱导的肺纤维化小鼠模型中的抗纤维化疗效和作用机制。材料与方法:制备ADR水提取物,并在气管内注射博莱霉素后以30、100和300毫克/千克的剂量口服给药10天。评估体重和肺组织学的变化。此外,还测量了支气管肺泡灌洗液(BALF)中炎症细胞的数量以及转化生长因子-β和α-平滑肌肌动蛋白(α-SMA)的水平。结果根据 Ashcroft 评分,ADR 治疗降低了组织学纤维化程度,减少了 BALF 中炎性细胞的数量。此外,肺组织中的α-SMA水平也有所下降。ADR剂量为300毫克/千克时,测量指标的下降幅度最大。结论结果表明,在特发性肺纤维化动物模型中,服用300毫克/千克ADR可减轻肺纤维化;因此,ADR可被视为肺纤维化的一种候选治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信